Alys Pharmaceuticals has today announced that the U.S. FDA and Health Canada | Santé Canada have cleared the Investigational New Drug / Clinical Trial Application for the study of ALY-101 in patients suffering with Alopecia Areata. This is a pivotal milestone for the Company and marks the first clinical study from the Alys pipeline following our $100m seed financing from Medicxi. ? ALY-101 is an intradermal injectable JAK1 siRNA-lipid conjugate, and the Phase 2a trial will evaluate its safety and efficacy across five sites in the US and Canada. It is the first clinical candidate to emerge from joint research between #Alys and the RNA Institute of UMass Chan Medical School, which is focused on developing siRNA therapies for dermatological use. ? You can read the full press release linked in the comments below. ? #IND #CTA #alopecia #clinicaltrial #dermatology
关于我们
Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments. Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics, and has a number of strategic collaborations with leading research institutions.
- 网站
-
alyspharma.com
Alys Pharmaceuticals的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 类型
- 私人持股
- 创立
- 2024
Alys Pharmaceuticals员工
动态
-
Alys was honored to be represented at this year's DDDS by Lars French : thank you for presenting our lead assets with clarity and enthusiasm!
Chairman, Dept. Dermatology Ludwig Maximilian University Hospital, Munich, Germany, Acting CMO Alys Pharmaceuticals & Past-President (2019-2023), International League of Dermatological Societies (ILDS)
Thanks to the organizers of the 8th Annual Dermatology Drug Development Summit in Boston for inviting me to speak in the session devoted to "Optimizing the delivery of dermatological agents to increase targeting specificity in inflammatory environments". ? Was a pleasure to highlight unmet needs in dermatology and innovative drug candidates in the pipeline of #AlysPharmaceuticals (www.alyspharma.com), including a unique #bispecific mAb that selectively antagonizes mast-cell c-Kit planned for clinical trials in chronic spontaneous urticaria, and a unique #siRNA platform technology with #Jak1 siRNA for transepidermal delivery and skin selective Jak1 silencing as its lead planned for clinical trials in atopic dermatitis. #ThibaudPortal, #JohnHarris, #BrianKim, #CraigMello, #CarineBlanchard, #ClaireBouixPeter, #EmmanuelVial, #JonnyFinlay, #OrlaCunningham
-